Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families.
S YadoG LuboshitsO HazanR OrMichael A FirerPublished in: Journal for immunotherapy of cancer (2019)
These data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD.
Keyphrases
- newly diagnosed
- mouse model
- end stage renal disease
- chronic kidney disease
- endothelial cells
- ejection fraction
- stem cell transplantation
- low dose
- randomized controlled trial
- bone marrow
- prognostic factors
- electronic health record
- physical activity
- stem cells
- machine learning
- acute lymphoblastic leukemia
- cell therapy
- free survival
- high dose
- hematopoietic stem cell
- data analysis